Dr Mark Mooney
Lecturer in Proteomics
Postal Address:
Institute of Agri-Food & Land Use
Queen's University Belfast
David Keir Building
Stranmillis Road
Belfast BT9 5AG
Room: 01.331
Telephone: +44 (0)28 9097 6537
Fax: +44 (0)28 9097 6513
Email: mark.mooney@qub.ac.uk
Research Profile
Mark obtained his BSc in Biotechnology from Dublin City University in 1995 and subsequently an MSc in Biomedical Sciences from the University of Ulster in 1996. Following research on novel anti-diabetic agents he was awarded a PhD from the University of Ulster in 2000. He then took up a Wellcome Trust postdoctoral position within the Diabetes Research Group at the University of Ulster investigating insulin derivatives as potential biomarkers for use in the monitoring of type 2 diabetes development and received the Best Young Investigator award by the Irish Endocrine Society for this work. In 2003 he moved to the Strathclyde Institute for Drug Research at the University of Strathclyde where he investigated the pharmacological and metabolic activity of novel anti-obesity drugs. Since 2005, Mark has being working within IAFLU on multi-centre research projects aimed at developing innovative effect-based bioanalysis techniques using proteomic profiling approaches in areas of food safety and with a particular focus on identifying chemical agent exposure in animals. The development of blood-based biomarker approaches based on this work may lead to high-throughput screening approaches to identify contaminated food at source, thereby protecting human health and ensuring consumer safety and confidence in food supply chains. Such an approach has been investigated for use in the identification of illicit growth promoter use in beef rearing processes and is currently being applied to the identification of exposure to a range of environmental and dietary chemical contaminants. It is envisaged that the predictive capability derived from this work will enable the early identification of chemical contamination events that do not produce overt clinical effects in animals, thus ensuring their rapid removal from the food chain and disrupting the pathway to human contamination at source. Other ongoing research projects centre on Bovine Respiratory Disease (BRD) and the identification of markers associated with effective and maintained immune status in vaccinated animals. This work aims to develop new technologies to enhance the efficacy of clinical diagnosis and vaccination procedures to facilitate more efficient management of BRD in herds.
Qualifications
- BSc in Biotechnology, 1995; Dublin City University
- MSc in Biomedical Sciences, 1996; University of Ulster
- PhD: Nutritional Endocrinology, 2000; University of Ulster
- PG Cert in Higher Education Teaching, 2008; Queen's University Belfast
Peer reviewed original research publications
Graham, S.F., Ruiz-Aracama, A., Lommen, A., Cannizzo, F.T., Biolatti, B., Elliott, C.T., Mooney, M.H. (2012). Use of NMR metabolomic plasma profiling methodologies to identify illicit growth-promoting administrations. Anal Bioanal Chem, DOI 10.1007/s00216-012-5815-z.
Campbell, K., McGrath, T.F., Sjolander, S., Hanson, T., Tidare, M., Jansson, O., Moberg, A., Mooney, M., Elliott, C., Buijs, J. (2011). Use of a novel micro-fluidic device to create arrays for multiplex analysis of large and small molecular weight compounds by surface plasmon resonance. Biosens Bioelectron, 26(6): 3029-3036.
Pinel, G., Weigel, S., Antignac, J.P., Mooney, M.H., Elliott, C., Nielen, M.W.F., LeBizec, B. (2010). Targeted and untargeted profiling of biological fluids to screen for anabolic practices in cattle. Trac-Trend Anal Chem, 29(11): S1 1269-1280.
Zong, H.L., Madden, A., Ward, M., Mooney, M.H., Elliott, C.T., Stitt, A.W. (2010). Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated Signal Transduction. J Biol Chem, 285(30): 23135-23144.
Situ, C., Buijs, J., Mooney, M.H., Elliott, C.T. (2010). Advances in surface plasmon resonance biosensor technology towards high-throughput food-safety analysis. Trac-Trend Anal Chem, 29(11): S1: 1305-1315.
Mooney, M.H., Le Bizec, B., Elliott, C.T. (2009). Combining biomarker screening and mass-spectrometric analysis to detect hormone abuse in cattle. Trac-Trend Anal Chem, 28(6): 665-675.
Duffy, E., Mooney, M.H., Elliott, C.T., O'Keeffe, M.(2009). Studies on the persistence of estradiol benzoate and nortestosterone decanoate in hair of cattle following treatment with growth promoters, determined by UPLC-MS/MS. J Chromatogr A, 1216(46): 8090-8095.
Duffy, E., Mooney, M.H., Elliott, C.T., O'Keeffe, M. (2009). Studies on the persistence of estradiol benzoate and nortestosterone decanoate in hair of cattle following treatment with growth promoters, determined by UPLC-MS/MS. J Chrom A., 1216(46): 8090-8095.
Mooney, M.H., Le Bizec, B., Elliott, C.T. (2009). Combining biomarker screening and mass-spectrometric analysis to detect hormone abuse in cattle. Trends Anal Chem, 28(6): 665-675.
Coxon, G.D., Furman, B.L., Harvey, A.L., McTavish, J., Mooney, M.H., Arastoo, M., Kennedy, A.R., Tettey, J.M., Waigh, R.D. (2009). Benzylguanidines and other galegine analogs inducing weight loss in mice. J Med Chem, 52(11): 3457-3463.
Mooney, M.H., Bergwerff, A.A., van Meeuwen, J.A., Luppa, P.B., Elliott, C.T. (2009). Biosensor-based detection of reduced sex hormone-binding globulin binding capacities in response to growth-promoter administrations. Anal Chim Acta, 637(1-2): 235-240.
Cunningham, R.T., Mooney, M.H., Xiao-Lei, X., Crooks, S., Matthews, D., O'Keeffe, M., Li, K., Elliott, C.T. (2009). Feasibility of a clinical chemical analysis approach to predict misuse of growth promoting hormones in cattle. Anal Chem, 81(3): 977-983.
Cacciatore, G., Eisenberg, S.W.F., Situ, C., Mooney, M.H., Delahaut, P., Klarenbeek, S., Huet, A.C., Bergwerff, A.A., Elliott, C.T. (2009). Effect of growth-promoting 17ß estradiol, 19 nortestosterone and dexamethasone on circulating levels of nine potential biomarker candidates in veal calves. Anal Chim Acta, 637(1-2): 351-359.
Mooney, M.H., Situ, C., Cacciatore, G., Hutchinson, T., Elliott, C., Bergwerff, A.A. (2008). Plasma biomarker profiling in the detection of growth promoter use in calves. Biomarkers, 13(3): 246-256.
Mooney, M.H., Fogarty, S., Stevenson, C.S., Gallagher, A.M., Palit, P., Hawley, S.A., Hardie, D.G., Coxon, G.C., Waigh, R.D., Tate, R.J. Harvey, A.L., Furman, B.L. (2008). Mechanisms underlying the metabolic actions of galegine that contribute to weight loss in mice. Brit J Pharmacol, 153: 1669-1677.
Cacciatore, G., Situ, C., Merckx, T., Mooney, M.H., Eisenberg, S. Delahaut, P., Elliott, C., de Pauw, E., Bergwerff, A.A. (2006). Biomarkers revealing abuse of steroid hormones. J Vet Pharmacol Therap, 29(S1): 143-144.
Irwin, N., Greer, B., Gault, V.A., Harriott, P., Green, B.D., Mooney, M.H., Flatt, P.R., Bailey, C.J., O'Harte, F.P.M. (2005). A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J Pharmacol Exp Ther., 314: 1187-94.
Green, B.D., Gault, V.A., Mooney, M.H., Irwin, N., Harriott, P., Greer, B., Bailey, C.J., O'Harte, F.P.M., Flatt, P.R. (2004). Degradation, receptor binding, insulin-secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues. Biol Chem, 385: 169-177.
Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., O'Harte, F.P.M., Flatt, P.R. (2004). N-terminal His7-modification of glucagon-like peptide-1(7-36)amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol, 180: 379-388.
Green, B.D., Mooney, M.H., Gault, V.A., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2004). Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagons-like peptide-1(9-36)amide and exendin(9-39). Metabolism, 53: 252-259.
Green, B.D., Gault, V.A., Irwin, N., Mooney, M.H., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2003). Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-subsituted analogues of glucagons-like peptide-1. Biol Chem, 384: 1543-1551.
Green, B.D., Gault, V.A., Mooney, M.H., Irwin, N., Bailey, C.J., Harriott, P., Greer, B., Flatt, P.R., O'Harte, F.P.M. (2003). Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol, 31: 529-540.
Lindsay, J.R., McKillop, A.M., Mooney, M.H., O'Harte, F.P.M., Flatt, P.R., Bell, P.M. (2003). The effect of nateglinide on the secretion of glycated insulin and glucose intolerance in type 2 diabetes. Diabetes Res Clin Pract, 61: 167-173.
Gault, V.A., O'Harte, F.P.M., Harriott, P., Mooney, M.H., Green, B.D., Flatt, P.R. (2003). Effects of the novel Pro3 GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Diabetologia, 52: 492-498, 2003.
Lindsay JR, McKillop, A.M., Mooney, M.H., O'Harte, F.P.M., Bell, P.M., Flatt, P.R. (2003). Demonstration of increased concentrations of circulating glycated insulin in human type 2 diabetes using a novel and specific radioimmunoassay. Diabetologia, 46: 475-478.
Lindsay JR, McKillop, A.M., Mooney, M.H., Flatt, P.R., Bell, P.M., O'Harte, F.P.M. (2003). Meal-induced 24-hour profile of circulating glycated insulin in type 2 diabetic subjects measured by a novel radioimmunoassay. Metabolism, 52: 631-635.
Gault, V.A., Flatt, P.R., , Harriott, P., Mooney, M.H., Bailey, C.J., O'Harte, F.P.M. (2003). Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotropic polypeptide. J Endocrinol, 176: 133-141, 2003.
Hunter, S.J., Boyd AC, O'Harte, F.P.M., McKillop, A.M., Wiggam, M.I., Mooney, M.H., McCluskey, J.T., Lindsay, J.R., Ennis, C.N., Gamble, R., Sheridan, B., Barnett, C.R., McNulty, H., Bell, P.M., Flatt, P.R. (2003). Demonstration of glycated insulin in human diabetic plasma and decreased biological activity assessed by euglycaemic-hyperglycemic clamp technique in humans. Diabetes, 52: 492-498.
McKillop, A.M., Abdel-Wahab, Y.H.A., Mooney, M.H., O'Harte, F.P.M., Flatt, P.R. (2002). Secretion of glycated insulin from pancreatic B-cells in diabetes represents a novel aspect of B-cell dysfunction and glucose toxicity. Diabetes Metab, 28: 3S61-3S69.
Gault, V.A., Flatt, P.R., Bailey, C.J., Harriott, P., Greer, B., Mooney, M.H., O'Harte, F.P.M. (2002). Enhanced cyclic AMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme resistant forms of GIP, is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem J, 367: 913-920.
O'Harte, F.P.M., Gault, V.A., Parker, J.C., Harriott, P., Mooney, M.H., Bailey, C.J., Flatt, P.R. (2002). Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia, 45: 1281-1291.
Mooney, M.H., Abdel-Wahab, Y.H.A., McKillop, A.M., O'Harte, F.P.M., Flatt, P.R. (2002). Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models. Biochim Biophys Acta, 1569: 75-80.
Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Mooney, M.H., Barnett, C.R., Flatt, P.R. (2002). Vitamin C supplementation decreases insulin glycation and improves glucose homeostasis in obese hyperglycaemic (ob/ob) mice. Metabolism, 51: 514-517.
Mooney, M.H., Abdel-Wahab, Y.H.A., Morgan, L.M., O'Harte, F.P.M., Flatt, P.R. (2002). Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob). Endocrine, 16: 167-171.
McKillop, A.M., Mooney, M.H., Harriott, P., Flatt, P.R., O'Harte, F.P.M. (2001). Evaluation of glycated insulin in diabetic animals using immunocytochemistry and radioimmunoassay. Biochem Biophys Res Commun, 286: 3 524-528, 2001.
O'Harte, F.P.M., Mooney, M.H., Kelly, C.M.N., McKillop, A.M., Flatt, P.R. (2001). Degradation and glycemic effects of His7-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice. Reg Pept, 96: 95-104.
McKillop, A.M., McCluskey, J.T., Boyd AC, Mooney, M.H., Flatt, P.R., O'Harte, F.P.M. (2000). Production and characterization of specific antibodies for evaluation of glycated insulin in plasma and biological tissues. J Endocrinol, 167: 153-163.
O'Harte, F.P.M., Mooney, M.H., Kelly, C.M.N., Flatt, P.R. (2000). Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide. J Endocrinol, 165: 639-648.
O'Harte, F.P.M., Mooney, M.H., Lawlor, A., Flatt, P.R. (2000). N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its anti-hyperglycaemic activity in vivo. Biochim Biophys Acta, 1474: 13-22.
Abdel-Wahab, Y.H.A., O'Harte, F.P.M., Mooney, M.H., Conlon JM, Flatt, P.R. (1999). N-terminal glycation of cholecystokinin-8 abolishes its insulinotropic action on clonal pancreatic B-cells. Biochim Biophys Acta, 1452: 60-67.
O'Harte, F.P.M., Mooney, M.H., Flatt, P.R. (1999). NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes, 48: 758-765.
O'Harte, F.P.M., Mooney, M.H., Kelly, C.M.N., Flatt, P.R. (1998). Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes, 47: 1619-1624.
